Medpace (MEDP) Stock Forecast, Price Target & Predictions
MEDP Stock Forecast
Medpace stock forecast is as follows: an average price target of $444.20 (represents a 26.31% upside from MEDP’s last price of $351.67) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
MEDP Price Target
The average price target for Medpace (MEDP) is $444.20 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $469.00 to $415.00. This represents a potential 26.31% upside from MEDP's last price of $351.67.
MEDP Analyst Ratings
According to 11 Wall Street analysts, Medpace's rating consensus is 'Buy'. The analyst rating breakdown for MEDP stock is 0 'Strong Buy' (0.00%), 7 'Buy' (63.64%), 4 'Hold' (36.36%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Medpace Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 01, 2024 | Jailendra Singh | Truist Financial | $415.00 | $382.52 | 8.49% | 18.01% |
| Jul 08, 2024 | Eric Coldwell | Robert W. Baird | $469.00 | $404.13 | 16.05% | 33.36% |
| Jun 13, 2024 | Eric Coldwell | Robert W. Baird | $456.00 | $403.74 | 12.94% | 29.67% |
| May 28, 2024 | Ann Hynes | Mizuho Securities | $435.00 | $390.55 | 11.38% | 23.70% |
| Apr 23, 2024 | David Windley | Jefferies | $450.00 | $376.26 | 19.60% | 27.96% |
| Feb 15, 2024 | John Sourbeer | UBS | $452.00 | $394.34 | 14.62% | 28.53% |
The latest Medpace stock forecast, released on Aug 01, 2024 by Jailendra Singh from Truist Financial, set a price target of $415.00, which represents a 8.49% increase from the stock price at the time of the forecast ($382.52), and a 18.01% increase from MEDP last price ($351.67).
Medpace Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 6 |
| Avg Price Target | - | $442.00 | $446.17 |
| Last Closing Price | $351.67 | $351.67 | $351.67 |
| Upside/Downside | -100.00% | 25.69% | 26.87% |
In the current month, the average price target of Medpace stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Medpace's last price of $351.67. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 29, 2024 | Cowen & Co. | - | Buy | Initialise |
| Apr 23, 2024 | Jefferies | - | Buy | Upgrade |
| Feb 15, 2024 | UBS | Neutral | Buy | Upgrade |
| Oct 24, 2023 | Barclays | - | Outperform | Upgrade |
| May 08, 2023 | Guggenheim | Neutral | Buy | Upgrade |
| Oct 27, 2022 | Goldman Sachs | - | Sector Weight | Downgrade |
| Oct 27, 2022 | HSBC | - | Buy | Upgrade |
| Oct 27, 2022 | Raymond James | - | Outperform | Upgrade |
| Oct 27, 2022 | RBC Capital | - | Sector Perform | Downgrade |
| Oct 27, 2022 | Keefe, Bruyette & Woods | - | Market Perform | Downgrade |
Medpace's last stock rating was published by Cowen & Co. on May 29, 2024. The company Initialise its MEDP rating from "null" to "Buy".
Medpace Financial Forecast
Medpace Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $460.87M | $434.07M | $394.10M | $383.74M | - | $330.95M | $308.55M | $295.57M | $278.29M | $259.96M | $259.68M | $230.37M | $205.00M | $230.88M | $229.89M | $216.24M |
| Avg Forecast | $732.59M | $713.95M | $682.98M | $657.81M | $632.56M | $615.71M | $590.86M | $569.37M | $554.37M | $542.42M | $528.40M | $512.39M | $498.72M | $475.79M | $433.75M | $401.80M | $386.01M | $357.17M | $344.01M | $327.09M | $309.04M | $291.56M | $272.10M | $265.29M | $245.96M | $218.58M | $182.50M | $226.32M | $222.37M | $217.15M |
| High Forecast | $751.76M | $732.63M | $700.84M | $675.02M | $649.11M | $631.81M | $606.32M | $584.26M | $568.88M | $544.24M | $542.23M | $525.80M | $511.76M | $476.71M | $445.10M | $412.32M | $396.11M | $366.51M | $344.01M | $329.32M | $311.14M | $293.55M | $273.95M | $267.10M | $247.63M | $220.07M | $183.75M | $227.86M | $223.89M | $218.62M |
| Low Forecast | $725.54M | $707.08M | $676.40M | $651.48M | $626.47M | $609.78M | $585.18M | $563.89M | $549.04M | $539.12M | $523.32M | $507.46M | $493.92M | $474.56M | $429.58M | $397.94M | $382.30M | $353.73M | $344.01M | $325.21M | $307.26M | $289.88M | $270.53M | $263.76M | $244.55M | $217.33M | $181.45M | $225.01M | $221.09M | $215.89M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | - | 1 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 7 | 11 | 10 | 10 | 11 | 6 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.08% | 1.02% | 1.07% | - | 1.01% | 1.00% | 1.01% | 1.02% | 0.98% | 1.06% | 1.05% | 1.12% | 1.02% | 1.03% | 1.00% |
Medpace's average Quarter revenue forecast for Sep 23 based on 5 analysts is $475.79M, with a low forecast of $474.56M, and a high forecast of $476.71M. MEDP's average Quarter revenue forecast represents a 3.24% increase compared to the company's last Quarter revenue of $460.87M (Jun 23).
Medpace EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | - | 1 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 7 | 11 | 10 | 10 | 11 | 6 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $83.63M | $92.16M | $82.33M | $89.27M | - | $69.31M | $60.32M | $59.05M | $47.68M | $52.69M | $60.47M | $51.36M | $34.78M | $39.95M | $41.15M | $34.77M |
| Avg Forecast | $141.88M | $138.27M | $132.28M | $127.40M | $122.51M | $119.25M | $114.43M | $110.27M | $107.37M | $105.05M | $102.34M | $56.18M | $96.59M | $92.15M | $84.01M | $51.07M | $74.76M | $52.49M | $66.63M | $46.43M | $57.97M | $47.72M | $44.00M | $46.10M | $54.85M | $50.96M | $16.91M | $40.38M | $35.66M | $34.77M |
| High Forecast | $145.60M | $141.89M | $135.74M | $130.73M | $125.72M | $122.37M | $117.43M | $113.16M | $110.18M | $105.40M | $105.02M | $67.42M | $99.12M | $92.33M | $86.20M | $61.29M | $76.72M | $62.99M | $66.63M | $55.72M | $69.56M | $57.26M | $52.81M | $55.31M | $65.82M | $61.15M | $20.29M | $48.46M | $42.79M | $41.73M |
| Low Forecast | $140.52M | $136.94M | $131.00M | $126.18M | $121.33M | $118.10M | $113.33M | $109.21M | $106.33M | $104.41M | $101.35M | $44.95M | $95.66M | $91.91M | $83.20M | $40.86M | $74.04M | $41.99M | $66.63M | $37.15M | $46.38M | $38.18M | $35.20M | $36.88M | $43.88M | $40.77M | $13.53M | $32.31M | $28.53M | $27.82M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 1.80% | 1.10% | 1.70% | - | 1.49% | 1.04% | 1.24% | 1.08% | 1.14% | 1.10% | 1.01% | 2.06% | 0.99% | 1.15% | 1.00% |
5 analysts predict MEDP's average Quarter EBITDA for Sep 23 to be $92.15M, with a high of $92.33M and a low of $91.91M. This is 10.19% upper than Medpace's previous annual EBITDA (Jun 23) of $83.63M.
Medpace Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | - | 1 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 7 | 11 | 10 | 10 | 11 | 6 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $61.07M | $72.89M | $68.67M | $66.03M | - | $61.31M | $50.03M | $48.57M | $39.93M | $43.31M | $50.87M | $41.46M | $24.10M | $28.95M | $29.81M | $23.98M |
| Avg Forecast | $128.05M | $124.19M | $120.80M | $117.91M | $108.27M | $104.60M | $102.88M | $100.50M | $92.50M | $89.68M | $81.45M | $48.87M | $71.25M | $65.66M | $61.43M | $44.43M | $57.29M | $42.45M | $41.99M | $40.39M | $47.23M | $38.59M | $36.67M | $37.24M | $46.35M | $40.69M | $11.64M | $28.57M | $25.84M | $23.98M |
| High Forecast | $132.41M | $128.41M | $124.91M | $121.92M | $111.95M | $108.15M | $106.38M | $103.92M | $95.65M | $92.58M | $84.22M | $58.64M | $73.67M | $66.94M | $63.51M | $53.31M | $59.24M | $50.93M | $41.99M | $48.46M | $56.68M | $46.30M | $44.01M | $44.69M | $55.62M | $48.82M | $13.97M | $34.28M | $31.01M | $28.77M |
| Low Forecast | $126.45M | $122.63M | $119.29M | $116.44M | $106.91M | $103.29M | $101.59M | $99.24M | $91.35M | $88.39M | $80.44M | $39.10M | $70.36M | $64.05M | $60.66M | $35.54M | $56.57M | $33.96M | $41.99M | $32.31M | $37.79M | $30.87M | $29.34M | $29.79M | $37.08M | $32.55M | $9.31M | $22.85M | $20.67M | $19.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 1.64% | 1.20% | 1.56% | - | 1.52% | 1.06% | 1.26% | 1.09% | 1.16% | 1.10% | 1.02% | 2.07% | 1.01% | 1.15% | 1.00% |
Medpace's average Quarter net income forecast for Sep 23 is $65.66M, with a range of $64.05M to $66.94M. MEDP's average Quarter net income forecast represents a 7.51% increase compared to the company's last Quarter net income of $61.07M (Jun 23).
Medpace SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | - | 1 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 7 | 11 | 10 | 10 | 11 | 6 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $39.40M | $38.03M | $33.40M | $35.42M | - | $29.37M | $27.66M | $28.05M | $26.97M | $25.74M | $22.38M | $22.80M | $21.86M | $25.12M | $21.26M | $29.12M |
| Avg Forecast | $70.42M | $68.63M | $65.65M | $63.23M | $60.80M | $59.18M | $56.80M | $54.73M | $53.29M | $52.14M | $50.79M | $23.41M | $47.94M | $45.74M | $41.69M | $21.28M | $37.11M | $24.51M | $33.07M | $19.34M | $26.11M | $22.28M | $24.77M | $22.13M | $20.40M | $22.37M | $10.55M | $29.18M | $23.04M | $34.18M |
| High Forecast | $72.26M | $70.42M | $67.37M | $64.89M | $62.40M | $60.73M | $58.28M | $56.16M | $54.68M | $52.31M | $52.12M | $28.09M | $49.19M | $45.82M | $42.78M | $25.53M | $38.08M | $29.41M | $33.07M | $23.21M | $31.34M | $26.74M | $29.73M | $26.56M | $24.47M | $26.84M | $12.67M | $35.02M | $27.64M | $41.01M |
| Low Forecast | $69.74M | $67.97M | $65.02M | $62.62M | $60.22M | $58.61M | $56.25M | $54.20M | $52.78M | $51.82M | $50.30M | $18.73M | $47.48M | $45.62M | $41.29M | $17.02M | $36.75M | $19.61M | $33.07M | $15.48M | $20.89M | $17.82M | $19.82M | $17.71M | $16.32M | $17.90M | $8.44M | $23.34M | $18.43M | $27.34M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.95% | 1.79% | 0.90% | 1.45% | - | 1.52% | 1.06% | 1.26% | 1.09% | 1.16% | 1.10% | 1.02% | 2.07% | 0.86% | 0.92% | 0.85% |
Medpace's average Quarter SG&A projection for Sep 23 is $45.74M, based on 5 Wall Street analysts, with a range of $45.62M to $45.82M. The forecast indicates a 16.07% rise compared to MEDP last annual SG&A of $39.40M (Jun 23).
Medpace EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | - | 1 | 5 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 7 | 11 | 10 | 10 | 11 | 6 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.00 | $2.35 | $2.20 | $2.13 | - | $1.75 | $1.39 | $1.35 | $1.11 | $1.21 | $1.43 | $1.16 | $0.68 | $0.80 | $0.82 | $0.67 |
| Avg Forecast | $3.99 | $3.87 | $3.76 | $3.67 | $3.37 | $3.26 | $3.21 | $3.13 | $2.88 | $2.79 | $2.54 | $2.47 | $2.22 | $2.05 | $1.91 | $1.82 | $1.79 | $1.47 | $1.31 | $1.26 | $1.25 | $1.08 | $0.99 | $1.00 | $1.24 | $1.07 | $0.40 | $0.74 | $0.76 | $0.71 |
| High Forecast | $4.13 | $4.00 | $3.89 | $3.80 | $3.49 | $3.37 | $3.32 | $3.24 | $2.98 | $2.89 | $2.62 | $2.55 | $2.30 | $2.09 | $1.98 | $1.88 | $1.85 | $1.52 | $1.31 | $1.27 | $1.26 | $1.09 | $1.00 | $1.01 | $1.25 | $1.08 | $0.40 | $0.75 | $0.76 | $0.72 |
| Low Forecast | $3.94 | $3.82 | $3.72 | $3.63 | $3.33 | $3.22 | $3.17 | $3.09 | $2.85 | $2.75 | $2.51 | $2.43 | $2.19 | $2.00 | $1.89 | $1.79 | $1.76 | $1.46 | $1.31 | $1.25 | $1.24 | $1.07 | $0.98 | $1.00 | $1.23 | $1.07 | $0.39 | $0.74 | $0.75 | $0.71 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.29% | 1.23% | 1.44% | - | 1.39% | 1.11% | 1.25% | 1.12% | 1.20% | 1.15% | 1.08% | 1.72% | 1.08% | 1.09% | 0.94% |
According to 5 Wall Street analysts, Medpace's projected average Quarter EPS for Sep 23 is $2.05, with a low estimate of $2.00 and a high estimate of $2.09. This represents a 2.31% increase compared to MEDP previous annual EPS of $2.00 (Jun 23).
Medpace Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CRL | Charles River Laboratories | $198.61 | $324.46 | 63.37% | Buy |
| LH | Laboratory Corporation of America | $221.13 | $287.00 | 29.79% | Buy |
| MEDP | Medpace | $351.67 | $444.20 | 26.31% | Buy |
| QGEN | Qiagen | $46.36 | $52.37 | 12.96% | Buy |
| IQV | IQVIA | $238.70 | $269.43 | 12.87% | Buy |
| NEOG | Neogen | $16.13 | $17.50 | 8.49% | Buy |
| ICLR | ICON Public Limited Company | $300.00 | $307.63 | 2.54% | Buy |
| RVTY | Revvity | $122.03 | $123.83 | 1.48% | Hold |
| WAT | Waters | $325.86 | $325.00 | -0.26% | Buy |
| MTD | Mettler-Toledo | $1.38K | $1.36K | -1.35% | Hold |
| IDXX | IDEXX Laboratories | $500.55 | $479.75 | -4.16% | Buy |
| TWST | Twist Bioscience | $46.95 | $41.20 | -12.25% | Buy |
MEDP Forecast FAQ
Is Medpace a good buy?
Yes, according to 11 Wall Street analysts, Medpace (MEDP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 63.64% of MEDP's total ratings.
What is MEDP's price target?
Medpace (MEDP) average price target is $444.2 with a range of $415 to $469, implying a 26.31% from its last price of $351.67. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Medpace stock go up soon?
According to Wall Street analysts' prediction for MEDP stock, the company can go up by 26.31% (from the last price of $351.67 to the average price target of $444.2), up by 33.36% based on the highest stock price target, and up by 18.01% based on the lowest stock price target.
Can Medpace stock reach $500?
MEDP's average twelve months analyst stock price target of $444.2 does not support the claim that Medpace can reach $500 in the near future.
What are Medpace's analysts' financial forecasts?
Medpace's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.41B (high $2.47B, low $2.39B), average EBITDA is $466.46M (high $478.67M, low $461.97M), average net income is $416.24M (high $430.4M, low $411.03M), average SG&A $231.51M (high $237.57M, low $229.29M), and average EPS is $12.97 (high $13.41, low $12.81). MEDP's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.79B (high $2.86B, low $2.76B), average EBITDA is $539.84M (high $553.96M, low $534.64M), average net income is $490.95M (high $507.65M, low $484.81M), average SG&A $267.93M (high $274.94M, low $265.35M), and average EPS is $15.3 (high $15.82, low $15.11).
Did the MEDP's actual financial results beat the analysts' financial forecasts?
Based on Medpace's last annual report (Dec 2022), the company's revenue was $1.46B, beating the average analysts forecast of $1.41B by 3.23%. Apple's EBITDA was $301.04M, beating the average prediction of $240.31M by 25.27%. The company's net income was $245.37M, beating the average estimation of $182.11M by 34.74%. Apple's SG&A was $131.4M, beating the average forecast of $114.02M by 15.24%. Lastly, the company's EPS was $7.58, beating the average prediction of $5.83 by 29.97%. In terms of the last quarterly report (Jun 2023), Medpace's revenue was $460.87M, beating the average analysts' forecast of $433.75M by 6.25%. The company's EBITDA was $83.63M, missing the average prediction of $84.01M by -0.45%. Medpace's net income was $61.07M, missing the average estimation of $61.43M by -0.58%. The company's SG&A was $39.4M, missing the average forecast of $41.69M by -5.49%. Lastly, the company's EPS was $2, beating the average prediction of $1.91 by 4.47%